Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 11:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cohort I Clear all
Terminated Phase 1 Interventional

Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma

NCT00053950
View directory record Official record
Conditions
Disseminated Neuroblastoma, Recurrent Neuroblastoma
Interventions
pyrazoloacridine, filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, laboratory biomarker analysis, pharmacological study
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy Volunteers

NCT05099510
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Natrunix, Placebo
Biological
Lead sponsor
XBiotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 1 Interventional

Sarcosinamide Nitrosourea in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00004079
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
SarCNU, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Sep 25, 2026, 11:05 PM EDT
Active, not recruiting Not applicable Interventional

Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy

NCT05831579
View directory record Official record
Conditions
Unresectable Solid Tumor, Metastatic Cancer
Interventions
Proton GRID Radiotherapy
Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 1 Interventional

Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma

NCT01554410
View directory record Official record
Conditions
Cervical Carcinoma
Interventions
Intensity Modulated Radiation Therapy (IMRT), Cisplatin, Gemcitabine
Radiation · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 2 Interventional Results available

ALL Adult Consortium Trial: Adult ALL Trial

NCT00476190
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Doxorubicin, Cytarabine, Methotrexate, Vincristine, Cyclophosphamide, Methylprednisone, Hydrocortisone Sodium Succinate, Dexamethasone, 6-MP, PEG-Asparaginase, Imatinib, Etoposide, Radiation Therapy, E. coli Asparaginase
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
7
States / cities
Boston, Massachusetts • New York, New York • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 1 Interventional Results available

Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors

NCT01310179
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Ad/PNP and fludarabine monophosphate
Genetic
Lead sponsor
PNP Therapeutics, Inc.
Industry
Eligibility
19 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Birmingham, Alabama • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Sep 25, 2026, 11:05 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

NCT03377387
View directory record Official record
Conditions
Breast Cancer
Interventions
Capecitabine, Neratinib, EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30
Drug · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
10
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 1 Interventional

Docetaxel and Lycopene in Metastatic Prostate Cancer

NCT01949519
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Lycopene and Docetaxel
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Sep 25, 2026, 11:05 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults

NCT07183709
View directory record Official record
Conditions
COVID-19
Interventions
PepGNP-COVID19, Sterile Water for Injection
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 25, 2026, 11:05 PM EDT
Recruiting Phase 1Phase 2 Interventional

Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors

NCT07095868
View directory record Official record
Conditions
Selected Types of Solid Tumor
Interventions
EVM14, Pembrolizumab
Biological · Combination Product
Lead sponsor
Everest Medicines (Beijing) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
New York, New York • Houston, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 25, 2026, 11:05 PM EDT
Terminated Phase 1Phase 2 Interventional

A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy

NCT01234519
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
AEZS-108, AEZS-108 at MTD
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Miami, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Sep 25, 2026, 11:05 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Intervention to Improve Parent Communication About Sexuality

NCT07672067
View directory record Official record
Conditions
HIV/STI Incidence, Communication About Health Information
Interventions
Parents ASSIST
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
12 Years to 100 Years
Enrollment
476 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Azacitidine and Lenalidomide for Acute Myeloid Leukemia

NCT01016600
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Lenalidomide, Azacitidine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 6, 2015 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 1 Interventional Results available

Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

NCT01059071
View directory record Official record
Conditions
Neuroblastoma
Interventions
DFMO, Etoposide
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
7
States / cities
Orange, California • Hartford, Connecticut • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid Tumors

NCT02092792
View directory record Official record
Conditions
Neoplasms
Interventions
DLYE5953A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 1 Interventional

Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy

NCT00793975
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
IMC-1121B, 1121B
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2013 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 1 Interventional Results available

Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants

NCT02256631
View directory record Official record
Conditions
HIV Infections
Interventions
VRC01, VRC01LS, VRC07-523LS
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
0 Days to 5 Days
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Fort Lauderdale, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 25, 2026, 11:05 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma

NCT02352831
View directory record Official record
Conditions
Pancreatic Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer
Interventions
Tosedostat, Capecitabine, Fresh tissue biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 1 Interventional Results available

UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT02222688
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
cirmtuzumab
Drug
Lead sponsor
Thomas Kipps
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Sep 25, 2026, 11:05 PM EDT
Recruiting Phase 1 Interventional

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

NCT07619313
View directory record Official record
Conditions
Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Cisplatin, Computed Tomography, Durvalumab, Fluorouracil, Gemcitabine, Irinotecan, Leucovorin, Ligritinib, Magnetic Resonance Imaging, Oxaliplatin, Zimberelimab
Procedure · Drug · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 25, 2026, 11:05 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

NCT05327023
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
donor lymphocyte infusion, Cyclophosphamide, Busulfan, Mycophenolate mofetil, Fludarabine, Sirolimus
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 25, 2026, 11:05 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML

NCT02255162
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Myelocytic Leukemia, Acute Myelogenous Leukemia, Acute Granulocytic Leukemia, Acute Non-Lymphocytic Leukemia
Interventions
Lenalidomide, HLA-mismatched stem-cell Microtransplantation, Cytarabine
Drug · Genetic
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults

NCT03611946
View directory record Official record
Conditions
Zika Virus
Interventions
Single dose of rZIKV/D4Δ30-713 (10^3 PFU) via subcutaneous injection (0.5ml), Single dose of placebo via subcutaneous injection (0.5ml)., Single dose of rZIKV/D4Δ30-713 (10^4 PFU) via subcutaneous injection (0.5ml)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 25, 2026, 11:05 PM EDT